<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2818861/" ref="ordinalpos=4665&amp;ncbi_uid=2601881&amp;link_uid=PMC2818861" image-link="/pmc/articles/PMC2818861/figure/F1/" class="imagepopup">Figure 1.  From: Estrogen Receptor <span class="highlight" style="background-color:">Signaling</span> in Lung Cancer. </a></div><br /><div class="p4l_captionBody">Available strategies to target the estrogen signaling pathway for lung cancer include 1) inhibition of the final step in the synthesis of estrogen, by inhibiting the enzyme aromatase with the inhibitor anastrozole; 2) down-regulation of classical ERs using the pure antiestrogen fulvestrant; 3) inhibition of GPR30-dependent signaling through the newly identified GPR30 antagonist, G15; 4) targeting the growth factor pathways that are activated by estrogens, mainly the EGF and VEGF pathways using the drugs gefitinib, erlotinib or vandetanib. These strategies can be used alone or in combination.</div></div>